索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]丁玲岩,马志芳.P2Y12受体拮抗剂替格瑞洛的临床应用[J].国际心血管病杂志,2016,01:35-38.
点击复制

P2Y12受体拮抗剂替格瑞洛的临床应用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年01期
页码:
35-38
栏目:
综述
出版日期:
2016-01-20

文章信息/Info

Title:
-
作者:
丁玲岩; 马志芳
251700 滨州市中心医院心血管内科
Author(s):
-
关键词:
P2Y12受体抑制剂; 替格瑞洛; 冠心病
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.01.011
文献标识码:
-
摘要:
替格瑞洛是新型P2Y12受体抑制剂。与氯吡格雷相比,替格瑞洛抗血小板作用更快速、强效及可逆,且血小板抑制作用不受肝脏CYP2C19基因多态性的影响。对于氯吡格雷无反应或低反应的患者,替格瑞洛能够更有效地防止不良事件的发生。替格瑞洛应用于急性冠脉综合征及经皮冠状动脉介入治疗(PCI)患者安全有效。该文主要介绍替格瑞洛的临床应用背景、药效学和药动学、临床效应及临床应用的进展。
Abstract:
-

参考文献/References

[1] Behan MW,Chew DP,Aylward PE.The role of antiplatelet therapy in the secondary prevention of coronary artery disease[J].Curr Opin Cardiol,2010,25(4):321-328.
[2] Marczewski MM, Postula M, Kosior D.Novel antiplatelet agents in the preventntion of cardiovascular complications focus on ticagrelor[J].Vasc Health Risk Manag,2010,1(6):419-429.
[3] 刘 鸣,张文全,王明瑜,等.冠脉介入围手术期及长期抗血小板治疗[J].国际心血管病杂志,2014,41(6):381-384.
[4] Qian C,Wang Y,Zhong Y, et al. Wogonin-enhanced reactive oxygen species-induced apoptosis and potentiated cytotoxic effects of chemotherapeutic agents by suppression Nrf2-mediated signlingin in HepG2 cells. [J] Free Radic Res,2014,48(5):607-621.
[5] Gurbel PA,Bliden KP, Hiatt BL,et al.Clopidogrel for coronary stenting:response variability,drug resistance,and the effect of pretreatment platelet reactivity[J].Circulation,2003,107(23):2908-2913.
[6] Angiolillo DJ,Fernandez-Ortiz A,Bernardo E,et al. Variability in individual responsiveness to clopidogrel clinical implications management, and future perspectives[J]. J Am Coll Cardiol,2007,49(14):1505-1516.
[7] Buonamici P,Marcucci R,Migliorini A,et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis[J]. J Am Coll Cardiol,2007,49(24):2312-2317.
[8] Zhou D, Andersson TB, Grimm SW. In vitroevaluation of potential drug-drug interactions with ticagrelor:cytochrome P450 reaction phenotyping,inhibition,induction,and differential kinetics[J].Drug Metab Dispos,2011,39(4):703-710.
[9] Teng R,Mitchell PD, Butler K.Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers[J].J Clin Pharm Ther,2012,37(4):467-468.
[10] Butler K,Teng R. Pharmacokinetics,phamacodynamics,and safety of ticagrelor in volunteers with mild hepatic impairment[J].J Clin Pharm, 2011,51(7):978-987.
[11] Butler K,Teng R. Pharmacokinetics,phamacodynamics,and safety of ticagrelor in volunteers with severe renal impairment[J].J Clin Pharm, 2012,52(9):1388-1398.
[12] Curial M,Nath E,Lang E.Novel antiplatelet agent use for acute coronary syndrome in the emergency department:a review[J].Cardiol Res Praet,2013,2013:127-270.
[13] Iyu,Glenn JR,White AE.et al.Mode of action of P2Y12 antagonists as in hibitors of platelet function[J].Thromb Hsemost,2011,105(1):96-106.
[14] Hagbers C,Svensson H,Gustafsson R,et al.The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature[J].Int J Cardiol,2010,142(2):187-192.
[15] Storey RF,Angiolillo DJ,Patil SB,et al. Inhibitory effects of tieagrelor compared with clopidogrel on platelet function in patients with acute caronary syndromes:the PLATO(PLATelet inhibition and patient Outcomes)PLATELET substudy[J].J Am Coll Cardiol,2010,56(18):1456-1462.
[16] Storey RF,Bliden KP,Patil SB,et al.Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor,aclopidogrel,or placebo in the ONSET/OFFSET study[J].J Am Coll Cardiol,2010,56(3):185-193.
[17] Serebmany VL. Adenosine release:a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial?[J].Am Heart J,2011,161(1):1-4.
[18] Nylander S, Femia EA, Scavone M,et al.Ticargrelor inhibits human platelet aggregation via adenosine in addtion to P2Y12 antagonism[J].J Thromb Haemost,2013,11(10):1867-1876.
[19] Wittfeldt A,Emanuelssan H,Brandmp-Wognsen G,et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans[J].J Am Coll Cardiol,2013,61(7):723-727.
[20] Wallentin L,Becker RC,Budaj A, et al.Ticargrelor versus clopiclogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,36(11):1045-1057.
[21] Marcucci R,Gori AM,Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay:a 12-month follow-up[J].Circulation,2009,119(2):237-242.
[22] 骆景光,韩 凌,杨 明,等.替格瑞洛对高血小板反应性高危非ST段抬高型急性冠脉综合征患者血小板聚集率的影响[J].国际心血管病杂志,2015,42(5):133-134.
[23] Gurbel PA,Bliden KP, Butler K, et al. Randomized double blindassessmet of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronar artery desease:the ONSET/OFFSET study[J].Circulation,2009,120(25):2577-2585.
[24] Zahno A, Brecht K, Bodmer M. et al. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro[J].British J Pharmacol,2010,161(2):393-404.
[25] Bouman HJ, Schomig E,van Werkum JW, et al. Paraoxonaselisa major determinant of clopidogrel efficacy[J].Nat Med,2011,17(1):110-116.
[26] Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes(PLATO): a randomized double-blind study[J].Lancet,2011,375(9711):283-293.
[27] 许维忠,刘 俊,陈金国,等.替格瑞洛治疗急性冠脉综合征的疗效和安全性观察[J].安徽医学,2015,36(1):40-44.
[28] Varenhorst C, Alstrm U, Scirica BM, et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery[J].J Am Coll Cardiol,2012,60(17):1623-1630.
[29] Verdoia M, Schaffre A, Barbieri L,et al. Benefits from new ADP-antagonists as comparedto clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management:a meta-analysis of randomized trials[J].J Cardiovasc Pharmacol,2014,63(4):339-350.
[30] Nanhwan MK, Ling S, Kodakandla M,et al. Chronic treatment with ticagrelor limits myocardial infarct size an adenosine and cyclooxygenase-2-dependent effect[J].Arterioscler Thromb Vasc Biol,2014,34(9):2078-2085.
[31] Kotsia A, Brilakis ES, Held C,et al. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome:Insights from the PLATelet inhibition and patient Outcomes(PLATO)trial[J].Am Heart J,2014,168(1):68-75.
[32] 2012 Writing Committee Members, Jneid H, Anderson JL, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction(updating the 2007 guideline and replacing the 2011 focused update)a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Circulation,2012,126(7):875-910.
[33] Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies the RESPOND study[J]. Circulation, 2010, 121(10): 1188-1199.

备注/Memo

备注/Memo:
通信作者:丁玲岩,Email:hellodly@163.com
更新日期/Last Update: 2016-01-20